Skip to content

Author

Michael Dougan

We have 3 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...

Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al. · 0 citations
Sep 2026

Abstract B119: Generation of an Endogenous PDAC-Specific TCR Transgenic Mouse

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies and remains largely refractory to chemotherapy and immunotherapy. Although KRAS inhibitors show promising initial efficacy, resistance rapidly emerges, and immunotherapy responses are mostly restricted to the rare subset of patients with micr...

Chong Zuo, Li Qiang, Madeline Fitzgibbon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.